Home › Funds › BERNZOTT CAPITAL ADVISORS › HALO
BERNZOTT CAPITAL ADVISORS position in HALO
HALOZYME THERAPEUTICS INC · Health Care
BERNZOTT CAPITAL ADVISORS reported holding 70,403 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q2 2025 13F filing — a position valued at US$3.7M, representing 1.87% of its reported portfolio and ranking #30 among its reported holdings. BERNZOTT CAPITAL ADVISORS has disclosed HALO holdings in 7 of the last 8 reported quarters, going back to Q3 2023.
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
How BERNZOTT CAPITAL ADVISORS's HALO position evolved
BERNZOTT CAPITAL ADVISORS first disclosed a stake in HALO in Q3 2023 at 171,808 shares (US$6.6M). The position peaked in Q2 2024 at 187,249 shares, worth US$9.8M. Across 7 filings, BERNZOTT CAPITAL ADVISORS increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2025) shows 70,403 shares valued at US$3.7M — a reduction of -31,357 shares quarter over quarter.. Notable position changes include a 27% trim in Q4 2023 (shares rose 10% over the following quarter), a 68% increase in Q1 2024 (shares rose 29% over the following quarter), a 31% trim in Q2 2025 (shares rose 41% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 171.81K | $6.56M | New |
| Q4 2023 | 124.98K | $4.62M | Reduce |
| Q1 2024 | 209.80K | $8.53M | Add |
| Q2 2024 | 187.25K | $9.80M | Reduce |
| Q4 2024 | 93.98K | $4.49M | New |
| Q1 2025 | 101.76K | $6.49M | Add |
| Q2 2025 | 70.40K | $3.66M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About HALO and 13F data
HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 43 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$196.5M), SNYDER CAPITAL MANAGEMENT L P (US$187.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding HALO
- CONGRESS ASSET MANAGEMENT CO 2.28M sh · $251.89M · Q3 2026
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 2.51M sh · $196.54M · Q2 2026
- SNYDER CAPITAL MANAGEMENT L P 2.40M sh · $187.54M · Q2 2026
- LOS ANGELES CAPITAL MANAGEMENT LLC 1.94M sh · $151.69M · Q2 2026
- WASATCH ADVISORS LP 1.05M sh · $115.88M · Q3 2026
- Stephens Investment Management Group LLC 1.39M sh · $109.02M · Q2 2026
- GW&K Investment Management, LLC 1.35M sh · $105.97M · Q2 2026
- Boston Trust Walden Corp 1.08M sh · $84.77M · Q2 2026
- LMR Partners LLP 45.00M sh · $65.81M · Q2 2026
- Mizuho Markets Cayman LP 834.50K sh · $65.32M · Q2 2026
More on BERNZOTT CAPITAL ADVISORS
FAQ
How long has BERNZOTT CAPITAL ADVISORS held HALO?
BERNZOTT CAPITAL ADVISORS has disclosed HALO holdings in 7 of the last 8 reported quarters, going back to Q3 2023.
What is BERNZOTT CAPITAL ADVISORS's current position in HALO?
As of Q2 2025, BERNZOTT CAPITAL ADVISORS holds 70.40K shares of HALO (HALOZYME THERAPEUTICS INC), valued at $3.66M, representing 1.87% of its reported portfolio and ranking #30.
Has BERNZOTT CAPITAL ADVISORS been buying or selling HALO?
In the latest 13F filing (Q2 2025), BERNZOTT CAPITAL ADVISORS reduced its position in HALO. The position peaked in Q2 2024 at 187.25K shares.
Which other funds hold HALO?
Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, SNYDER CAPITAL MANAGEMENT L P, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.